Sorafenib and one of its derivatives (SC-1) have been reported to inhibit EGFR wild-type NSCLC growth and induce apoptosis via the SHP-1/STAT3 pathway [43]. This evidence concerns the gene STAT3 and non-small cell lung carcinoma.